Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Induction chemotherapy delivers first survival benefit in locally advanced cervical cancer for two decades
  • News

Induction chemotherapy delivers first survival benefit in locally advanced cervical cancer for two decades

  • 17 November 2023
  • Janet Fricker
Induction chemotherapy delivers first survival benefit in locally advanced cervical cancer for two decades
Total
0
Shares
0
0
0
0
0

A short course of induction chemotherapy prior to chemoradiation improved survival in locally advanced cervical cancer. The study, presented in a Presidential Symposium at the ESMO 2023 Congress, abstract LBA8, found that induction chemotherapy (paclitaxel and carboplatin) prior to chemoradiation taken for just six weeks reduced the risk of death by 39% and disease progression by 35%.

“Induction chemotherapy with weekly paclitaxel and carboplatin delivered immediately before chemoradiation should be considered the new standard in locally advanced cervical cancer and is feasible across diverse healthcare settings, including low- and middle-income countries,” said Mary McCormack, the study lead from UCL Cancer Institute, London, and University College Hospital, London.

In 2020 there were 604,000 new cases of cervical cancer worldwide and 324,000 deaths, of which 90% occurred in low- and middle-income countries. Since 1999 the standard of care for locally advanced cervical cancer has been cisplatin-based concurrent chemoradiation followed by brachytherapy. However, despite such treatment, up to 30% of patients will still relapse and die from metastatic disease.

For the GCIG (Gynecologic Cancer InterGroup) Interlace study, the investigators postulated that a short course of weekly ‘dose-dense’ paclitaxel and carboplatin chemotherapy before chemoradiation might downstage local disease, lengthen the exposure to systemic treatment and improve outcomes. A single-arm feasibility study, published in the British Journal of Cancer in 2013, involving 46 patients, demonstrated a good response rate to short-course weekly induction chemotherapy delivered before standard chemoradiation.

“The rationale was that the dose-dense schedule might overcome potential resistance and, by avoiding the gap between chemotherapy and radiotherapy, you limit the potential for tumour regrowth,” McCormack told Cancerworld. The team also introduced paclitaxel, since taxanes have been shown to be highly active in gynaecological cancers.

In the phase III GCIG Interlace study, between 2012 and 2022, 500 patients with newly diagnosed squamous, adeno, or adenosquamous cervical cancer, stage range from IB1 node positive to IVA, were randomised 1:1 to the experimental arm, where they received initial induction chemotherapy followed by standard chemoradiation (n=250) or to standard chemoradiation alone (n=250). In the experimental arm, patients received induction therapy with carboplatin at area-under-the-curve 2 plus paclitaxel at 80 mg/m2 once per week for six weeks before beginning chemoradiation in week seven. In both arms, chemoradiation consisted of 40 mg/m2 of cisplatin once every week for five weeks plus external beam radiation ranging from 40 Gy to 50.4 Gy, given in 20 to 28 fractions plus brachytherapy, to give a minimum total biologically equivalent dose of 78 Gy to Point A. It was later recommended that patients receive image-guided adaptive brachytherapy. Participants, who had a median age of 46 years, were recruited from 32 centres across the UK and from Mexico, India, Italy, and Brazil.

Results showed that around 75% of enrolled participants presented with stage IIA or IIB disease, 82% showed squamous histology, and almost 60% were node negative. Adherence to induction chemotherapy was high, with more than 90% receiving at least five cycles of induction chemotherapy, and more than 90% adhered to radiotherapy in both study arms.

Results at five years showed that patients in the combination therapy arm had a survival rate of 80% versus 72% in the chemoradiation alone arm (HR 0.61; 95%CI 0.40–0.91, P=0.04). Additionally, progression free survival was 73% in the combination therapy group vs 64% in the chemoradiation alone arm (HR 0.65; 95%CI 0.46–0.91, P=0.013). Notably, the rate of local and pelvic relapses was 16% in both arms, but the proportion of women with distant relapses was 12% in the combination arm vs 20% in the chemoradiation alone arm. “The reduction in distant relapses suggests that the induction chemotherapy is treating micro metastatic disease,” said McCormack.

Rates of grade 3 or worse adverse events were 59% for the combination therapy group and 48% for the chemoradiation alone arm. Any grade haematologic adverse event was reported in 30% of patients in the combination arm vs 13% in the standard chemoradiation alone arm, including neutropenia (19% vs 5%), anaemia (5% vs 4%), and thrombocytopenia (5% vs 2%). “As anticipated, haematologic toxicity was greater in the experimental arm, but this did not compromise the delivery of chemotherapy,” said McCormack.

The large magnitude of benefit, added McCormack, was all the more impressive given that the duration of additional treatment was only six weeks. “Many of the other advances in frontline treatment of cervical cancer, whilst very welcome, have only been shown to reduce the chances of cancer recurring, but have not yet shown improvement in survival. The duration of treatment with the immunotherapy drugs is two years,” she said.

Next the team plan to conduct a subgroup analysis looking at outcomes according to the nodal status of patients, to understand the suitability of the approach for different risk groups. Going forward, McCormack said, it would be interesting to explore whether induction chemotherapy can be combined with immunotherapy.

The discussant, Kishnansu Tewari, from University of California, Irvine, said, “This is the first phase III trial in locally advanced cervical cancer to show a survival benefit in over two decades. Importantly this study is using drugs that are readily available and physicians taking care of these patients could consider induction chemotherapy with paclitaxel and carboplatin tomorrow morning. In those parts of the world where there may not be access to checkpoint inhibitors, patients will have this option of induction chemotherapy followed by definitive chemoradiation.”

However, whether patients with node negative stage IIA or IIB cervical cancer need induction chemotherapy was open to question. “They are probably curable with standard chemoradiation plus brachytherapy. The real risk is for stage IIIB and stage IVA patients,” he said.

Opening illustration: The map shows age-standardised mortality rates from cervical cancer in 2020. Data are from the GLOBOCAN database, collated by the International Agency for Research on Cancer and hosted by the Global Cancer Observatory
Source: Deependra Singh, Jerome Vignat, Valentina Lorenzoni, et al (2022) Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Global Health 11(2):e197–e206
© 2022 World Health Organization
Republished under a Creative Commons Attribution-Noncommercial-NoDerivs IGO (CC BY-NC-ND 3.0 IGO) licence

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • adjuvant chemotherapy
  • brachytherapy
  • carboplatin
  • chemoradiation
  • cost-effectiveness
  • global cancer
  • induction chemotherapy
  • locally advanced cervical cancer
  • paclitaxel
  • survival benefit
  • sustainable
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Senza categoria

The cardiovascular system – what we’ve learned since our ‘cave man’ days

  • 17 November 2023
  • Francesca Albini
View Post
Next Article
  • Articles
  • Policy

Further and faster: ECO mobilises to accelerate momentum from Europe’s Beating Cancer Plan

  • 30 November 2023
  • Anna Wagstaff
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.